prepare for the unwanted

Predicting adverse effects
before they happen


Ideal assays for determining the specificity or unwanted activity of ADCC inducing compounds

A recent successful range of therapeutic antibodies  depend on effector functions for their mode-of-action. Here the constant fc-regions of the antibody interact with fc-receptors on the surfaces of immune cells.

Such interactions can result in the killing of a target cell, e.g., a virus-infected cell, through immune effector processes like antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). In addition, the fc-region can bind to the complement component C1q and cause complement-dependent cytotoxicity (CDC).

While these effects are something that these new therapeutics is harnessing in the treatment of different disease, in particular different cancer forms, the existence of such effects must be thoroughly investigated to ensure the safety of the drug and to avoid adverse effects.

NEW ADCC White Paper

See how our ADCC system performs and how it compares to that of a leading competitor in terms of sensitivity and dynamic range. Now updated with more data!

Unwanted ADDC activity
A threat to treatment efficacy and a potential safety concern

Regardless if it is specifically described for the Mechanism of Action (MOA) of the therapeutic antibody - if the molecule possesses an Fc region capable of binding to the effector cells of the immune system, the possibility of Fc Activity cannot be excluded and evaluation of potential ADCC activity must be performed. This has been requested by the Regulators in Europe.

When assessing Monoclonal Ab the typical adverse effects/issues to investigate could be:
  • Check for unwanted immune cell depletion by FcγRs cross-linking
  • Assess if the drug has any adverse effects, meaning can the therapeutic substance, intended for another MOA, adversely trigger an ADCC response
  • Confirming the absence of undesired ADCC effect


Our iLite® ADCC Reporter Bioassays are designed for evaluation of ADCC activity of therapeutic monoclonal antibodies (mAbs) with low variability.

Svar Life Science offer target cells with invalidated drug target expression that are ideal controls for determining the specificity and unspecific activity of an ADCC assay. Our assays offer an easier workflow than traditional ADCC assays, as well as an increased dynamic range and assay window.

To characterize your product with respect to ADCC activation Svar offers:

  • ADCC Effector Cells
  • + & - Target Cells for targets such as:
    CD20, EGFR, HER2, mTNF-alpha, mVEGF  etc.
Partner up with us and get a full-service solution where systems can be developed tailored to your specific needs, and subsequent we are available to assist with running the same assays.


Need help determining the specificity or unwanted activity of ADCC inducing compounds?


Contact us if you have questions, or would like to discuss your specific needs!

Contact us

Fill out the form

We'll put you in touch with one of our experienced scientists